Orforglipron and Heart Events in People With Heart Artery Disease or Chronic Kidney Disease
Tests orforglipron against placebo for heart problems in adults with artery or kidney disease.
Plain-language title generated from the registry record
Registry title: A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Key facts
- Where
- Brampton, Cambridge, Chicoutimi, Hamilton, Laval, Moncton, Montreal, Québec, Sarnia, Scarborough, Surrey, Trois-Rivières, Waterloo, Winchester, Windsor, and Winnipeg, CanadaSee the 19 sites
- Phase
- Phase 3
Where in Canada
- Centricity Research Brampton EndocrinologyBrampton, CanadaTaking people
- Cambridge Cardiac Care CentreCambridge, CanadaTaking people
- Ecogene-21Chicoutimi, CanadaTaking people
- Premier Clinical Trial NetworkHamilton, CanadaTaking people
- The Wharton Medical Clinic Clinical Trials IncHamilton, CanadaTaking people
- THEO Medical ConcordeLaval, CanadaTaking people
- G A Research AssociatesMoncton, CanadaTaking people
- Applied Medical Informatics ResearchMontreal, CanadaTaking people
- CHU de Quebec-Universite Laval-Hotel Dieu de QuebecQuébec, CanadaTaking people
- Diex Recherche Inc. Division QuebecQuébec, CanadaTaking people
- Bluewater Clinical Research Group Inc.Sarnia, CanadaTaking people
- Heart Health Institute - Scarborough OfficeScarborough, CanadaTaking people
- Kidney Care Centre - SurreySurrey, CanadaTaking people
- C.I.C. Mauricie inc.Trois-Rivières, CanadaTaking people
- Diex Recherche Inc. Division Trois-RivieresTrois-Rivières, CanadaTaking people
- Clinical Research Solutions - KitchenerWaterloo, CanadaTaking people
- Winchester District Memorial HospitalWinchester, CanadaTaking people
- Glanz Medicine Professional CorporationWindsor, CanadaTaking people
- Seven Oaks General HospitalWinnipeg, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07241390EU 2025-523123-22-00
- Record updated
- 4 November 2026
- Original description
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.Read full original descriptionShow less
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants With Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.
Inclusion: Have established ASCVD and/or CKD.
Exclusion: Have had a major heart condition within 60 days prior to screening; Have type 1 diabetes; Have New York Heart Association Functional Classification Class IV heart failure.